文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

REQUITE队列前列腺癌放疗后早期与晚期CTCAE及患者报告结局

Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-07-02

基于REQUITE国际多中心前瞻性队列,纳入7个欧洲国家和美国的1760例非转移性前列腺癌患者,按治疗方式分层,前瞻性采集放疗前、急性及晚期至放疗后8年的GI与GU症状。结果显示,真实世界队列中GI和GU症状的频率与分布与大型干预试验相当,多数患者同意将数据用于未来癌症研究。

要点

  • 真实世界前列腺癌放疗队列的GI和GU症状频率与大型干预试验相当。
  • EBRT单药者晚期≥2级脱肠炎12.1%、血尿12.9%,前列腺切除术后EBRT者尿失禁32.4%。
  • 3级不良事件总体低于1.5%,仅前列腺切除术后晚期尿失禁达10.2%。

核心结论

  • 真实世界多中心前列腺癌放疗队列中GI和GU症状的频率与分布与大型干预试验所报告的结果相当。
  • 该发现凸显了REQUITE等项目标准化数据采集方法的价值。

研究设计与样本

  • 国际多中心前瞻性队列研究(REQUITE),纳入7个欧洲国家和美国的1760例非转移性前列腺癌患者。
  • 2014至2016年按当地方案行根治性EBRT和/或近距离治疗,放疗前、急性及晚期随访至放疗后8年。
  • GI、GU症状(含性功能障碍)由医疗专业人员按CTCAE v4.0前瞻性评估,并采集患者报告结局。

主要发现

  • EBRT单药治疗患者中,临床医生报告的≥2级长期GI和GU症状发生率最高者为脱肠炎12.1%和血尿12.9%。
  • 前列腺切除术后/EBRT患者中,≥2级长期症状发生率最高者为脱肠炎6.4%和尿失禁32.4%。
  • 3级不良事件发生率低于1.5%,唯一例外为前列腺切除术后患者的晚期尿失禁(10.2%)。

关键数值与推荐

  • ≥2级长期GI症状:EBRT单药者脱肠炎12.1%;前列腺切除术后/EBRT者脱肠炎6.4%。
  • ≥2级长期GU症状:EBRT单药者血尿12.9%;前列腺切除术后/EBRT者尿失禁32.4%。
  • 3级不良事件发生率低于1.5%,前列腺切除术后晚期尿失禁为10.2%。

临床怎么用

  • 可参考本队列中各治疗方式分层下GI和GU症状的发生频率,用于前列腺癌放疗前患者咨询与随访规划。
  • 对前列腺切除术后接受EBRT的患者,应重点关注晚期尿失禁的评估与管理。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prospectively collected long-term adverse event data with pre-radiotherapy assessment and regular follow-up reflecting 'real world settings' are still limited. Here, we present the available data on early and long-term outcomes up to eight years after radiotherapy in men with prostate cancer who participated in the international REQUITE cohort study, stratified by treatment modalities and patient characteristics. METHODS: Longitudinal data on pre-radiotherapy, acute and late symptoms up to eight years after radiotherapy were available from 1760 non-metastatic prostate cancer patients recruited in seven European countries and the USA. External beam radiotherapy (EBRT) and/or brachytherapy were given with curative intent between 2014 and 2016 according to local regimens. Gastrointestinal (GI) and genitourinary (GU) symptoms including sexual dysfunction were prospectively assessed by healthcare professionals according to CTCAE v4.0. Patient-reported outcomes were collected. RESULTS: The highest incidence of clinician-reported grade ≥ 2 long-term GI and GU symptoms were for proctitis (12.1%) and haematuria (12.9%) among the EBRT-only treated patients, and proctitis (6.4%) and urinary incontinence (32.4%) among the post-prostatectomy/EBRT patients. Incidence of grade 3 adverse events was below 1.5%, with the only exception of late urinary incontinence in post-prostatectomy patients (10.2%). CONCLUSION: The frequency and distribution of GI and GU symptoms in a real-world multicentre cohort of patients following prostate radiotherapy were comparable to those reported in large interventional trials. Our finding highlights the value of standardised data farming approaches like the REQUITE project. Most patients consented to provide their data for future cancer research which is available on request.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Heumann P, Romero JCR, Aguado Barrera ME, et al. Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort. Clin Transl Radiat Oncol. 2026. PMID: 42500362. doi:10.1016/j.ctro.2026.101219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。